Pfizer Inc., US7170811035

Pfizer stock: Blackstone to fund obesity drug program

Published on 11/21/2026 at 11:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Pfizer stock enters the week with a new funding agreement for its obesity program. Blackstone will provide up to 1.5 billion US dollars through 2028 while Pfizer keeps control.

Funding supports obesity pipeline

  • Pfizer announced a strategic co-funding agreement with Blackstone on November 11, 2026.
  • The arrangement is designed to support clinical development of the monthly GLP-1 candidate berobenatide.
  • Pfizer retains operational control and decision-making for the program.
Pfizer Inc., US7170811035, Illustration mit AI erstellt.

Pfizer announced a strategic funding agreement with Blackstone Life Sciences on November 11, 2026, giving the drugmaker additional support for the clinical development of its obesity candidate berobenatide. The agreement is relevant to investors because it shifts part of the program's development funding to an external capital partner.

Under the agreement, funds managed by Blackstone will pay up to 1.5 billion US dollars of development costs through 2028. In return, Blackstone may receive milestone-based payments if the monthly injectable treatment wins US regulatory approval for chronic weight management and reaches specified commercial sales milestones.

Pfizer keeps program control

The agreement does not give Blackstone rights or ownership in berobenatide. Pfizer retains full operational control and decision-making authority, while milestone payments, if earned, would be made over several years. The financial outcome therefore depends on clinical progress, regulatory decisions and eventual commercial performance.

Pfizer said the arrangement is intended to advance its obesity program while preserving financial flexibility for investments across its broader pipeline. The company plans 10 ongoing or planned Phase 3 trials for berobenatide, an investigational monthly GLP-1 receptor agonist being studied for chronic weight management and obesity-related conditions.

The announcement came as Pfizer works to expand its cardiometabolic pipeline. For investors, the agreement offers external support for a costly development program, while the future payments to Blackstone create a contingent economic obligation tied to regulatory and sales milestones.

Pfizer company facts

  • Company: Pfizer Inc.
  • ISIN: US7170811035
  • Ticker: PFE
  • Primary exchange: New York Stock Exchange
  • Program: Berobenatide clinical development

Pfizer's agreement with Blackstone was announced in the company's investor release.

The broader market context is covered in Current market reports.

More news and analyses on Pfizer stock.

Disclaimer...
en | US7170811035 | PFIZER INC. | boerse | 70542144 | bgmi